- Home
- IPSC
as 06-20-2025 4:00pm EST
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 54.7M | IPO Year: | 2021 |
| Target Price: | $3.33 | AVG Volume (30 days): | 868.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.34 - $3.29 | Next Earning Date: | 08-07-2025 |
| Revenue: | $114,898,000 | Revenue Growth: | 8286.72% |
| Revenue Growth (this year): | 1064.82% | Revenue Growth (next year): | -89.54% |
Stock Insider Trading Activity of Century Therapeutics Inc. (IPSC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Farid Adrienne | IPSC | Chief Operations Officer | Jun 9 '25 | Sell | $0.62 | 552 | $343.34 | 250,141 | |
| Pfeiffenberger Brent | IPSC | President and CEO | Jun 9 '25 | Sell | $0.62 | 475 | $295.45 | 1,681,783 | |
| Russotti Gregory | IPSC | See Remarks | Jun 9 '25 | Sell | $0.62 | 526 | $327.17 | 392,047 | |
| Carr Douglas | IPSC | SVP Finance & Operations | Jun 9 '25 | Sell | $0.62 | 4,904 | $3,050.29 | 405,982 | |
| Pfeiffenberger Brent | IPSC | President and CEO | May 16 '25 | Sell | $0.55 | 29,552 | $16,135.39 | 1,681,783 | |
| Farid Adrienne | IPSC | Chief Operations Officer | May 5 '25 | Sell | $0.55 | 1,024 | $563.20 | 250,141 | |
| Carr Douglas | IPSC | SVP Finance & Operations | May 5 '25 | Sell | $0.55 | 295 | $162.25 | 405,982 |
Latest Century Therapeutics Inc. News
IPSC Breaking Stock News: Dive into IPSC Ticker-Specific Updates for Smart Investing
Zacks
15 days ago
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
GlobeNewswire
23 days ago
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
MT Newswires
a month ago
Chardan Trims Price Target on Century Therapeutics to $6 From $7, Maintains Buy Rating
Zacks
a month ago
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
GlobeNewswire
a month ago
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Zacks
2 months ago
Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
GlobeNewswire
2 months ago
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
GlobeNewswire
2 months ago
Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025
Compare IPSC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPSC Century Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.